NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX stock has decreased by 7.9% and is now trading at $3.8409. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) posted its earnings results on Thursday, May, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.30. Vaccinex had a negative net margin of 4,740.03% and a negative return on equity of 2,277.96%. View Vaccinex's earnings history.

1 analysts have issued 12-month target prices for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 472.8% from the stock's current price. View analysts' price targets for Vaccinex.

News stories about VCNX stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vaccinex earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutVaccinex.

Vaccinex saw a increase in short interest in May. As of May 15th, there was short interest totaling 190,000 shares, an increase of 13.2% from the April 30th total of 167,900 shares. Based on an average trading volume of 38,000 shares, the days-to-cover ratio is presently 5.0 days. Approximately 6.4% of the shares of the stock are short sold. View Vaccinex's Current Options Chain.

Some companies that are related to Vaccinex include Agile Therapeutics (AGRX), REDHILL BIOPHAR/S (RDHL), Spero Therapeutics (SPRO), Mallinckrodt (MNK), Marinus Pharmaceuticals (MRNS), Fortress Biotech (FBIO), Northwest Biotherapeutics (NWBO), Affimed (AFMD), Hookipa Pharma (HOOK), MediciNova (MNOV), XOMA (XOMA), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), LifeVantage (LFVN) and Iterum Therapeutics (NRBO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Vaccinex's stock is owned by many different retail and institutional investors. Top institutional investors include MSD Partners L.P. (7.10%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View institutional ownership trends for Vaccinex.

VCNX stock was sold by a variety of institutional investors in the last quarter, including MSD Partners L.P.. View insider buying and selling activity for Vaccinex.

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $3.84.

Vaccinex has a market capitalization of $63.95 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]